IMNM Stock: Price, Earnings History and SEC Filings
Immunome, Inc. (IMNM) last traded at $18.21, down 0.44% on the latest session and down 15.3% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $-0.65 against an analyst estimate of $-0.51, a miss of 27.5%.
$18.21 -0.44%
1 month-15.34%
52-week high$30.06
52-week low$14.64
Volume1.27M
ExchangeNasdaqCM
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
IMNM earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 11, 2026 | $-0.65 | $-0.51 | -27.45% |
| Mar 2026 | May 12, 2026 | $-0.48 | $-0.60 | +20.00% |
| Dec 2025 | Mar 3, 2026 | $-0.75 | $-0.65 | -15.38% |
| Sep 2025 | Nov 6, 2025 | $-0.65 | $-0.57 | -14.04% |
IMNM beat the analyst EPS estimate in 1 of its last 4 reported quarters. Source: Nasdaq.
Latest SEC filings for IMNM
SEC filing data is not available right now. You can search for IMNM on SEC EDGAR.
IMNM news
- Immunome Announces EMA Validation of Marketing Authorization Application for Varegacestat for the Treatment of Adults with Desmoid TumorsOct 30, 2026 · finance.yahoo.com
- Immunome Presents Additional Clinical Data for Varegacestat in Desmoid Tumors at ESMO 2026Oct 26, 2026 · finance.yahoo.com
- William Blair Expands Biotech Research as Veteran Analyst Alethia Young Initiates CoverageOct 21, 2026 · finance.yahoo.com
About Immunome, Inc.
Immunome, Inc. (IMNM) is a US-listed public company on Nasdaq.